Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
PRIMARY OBJECTIVES:

Determine the safety and tolerability of nilotinib in steroid dependent / refractory cGVHD.

SECONDARY OBJECTIVES:

Determine the clinical efficacy of nilotinib in steroid dependent / refractory cGVHD.
Bone Marrow Transplant Failure|Lymphoma, Non-Hodgkin|Lymphoma, T-Cell, Peripheral
DRUG: Nilotinib
Frequency and severity of adverse events graded according to CTCAE v4.0, 2 years
Chronic GVHD response measured as change in physical exam and laboratory testing, baseline and 2 years|Chronic GVHD response measured as change in daily corticosteroid requirement, baseline and 2 years|Chronic GVHD response measured as frequency of treatment failure defined as discontinuation of study drug due to severe adverse effects or initiation of a new treatment for cGVHD, 2 years|Chronic GVHD response measured as change in cGVHD symptom burden, baseline and 2 years
PRIMARY OBJECTIVES:

Determine the safety and tolerability of nilotinib in steroid dependent / refractory cGVHD.

SECONDARY OBJECTIVES:

Determine the clinical efficacy of nilotinib in steroid dependent / refractory cGVHD.